We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
-23.11%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$124M
AUM Growth
-$37.4M
Cap. Flow
+$4.08M
Cap. Flow %
3.3%
Top 10 Hldgs %
86.46%
Holding
31
New
6
Increased
8
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$18.5M
2
ELEV
Elevation Oncology
ELEV
+$3.36M
3
LVTX
LAVA Therapeutics
LVTX
+$2.18M
4
KZR
Kezar Life Sciences
KZR
+$2.18M
5
ADVM
Adverum Biotechnologies
ADVM
+$2.14M

Top Sells

Rank Stock Value
1
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$26.1M
2
WHWK
Whitehawk Therapeutics
WHWK
+$548K
3
PVLA
Palvella Therapeutics
PVLA
+$506K
4
ACHL
Achilles Therapeutics
ACHL
+$384K
5
LENZ
LENZ Therapeutics
LENZ
+$268K

Sector Composition

Rank Sector Weight
1 Healthcare 98.84%
2 Technology 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVIR icon
1
Atea Pharmaceuticals
AVIR
$390M
$22.8M 18.41%
7,609,812
+1,500
+0% +$4.68K
ACRS icon
2
Aclaris Therapeutics
ACRS
$793M
$21.8M 17.65%
14,250,000
– –
THRD
3
DELISTED
Third Harmonic Bio
THRD
$13.3M 10.74%
+3,824,417
New +$18.5M
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$12M 9.7%
2,742,317
+474,253
+21% +$2.14M
ANTX icon
5
AN2 Therapeutics
ANTX
$169M
$7.82M 6.33%
5,749,432
– –
TIL icon
6
Instil Bio
TIL
$50.3M
$7.23M 5.85%
416,720
+16,720
+4% +$347K
EPIX
7
DELISTED
ESSA Pharma
EPIX
$6.67M 5.4%
4,221,546
– –
ORMP icon
8
Oramed Pharmaceuticals
ORMP
$165M
$6.46M 5.23%
3,020,748
+376,841
+14% +$869K
IMA
9
ImageneBio Inc
IMA
$60.7M
$4.75M 3.84%
309,234
+10,412
+3% +$180K
PMVP icon
10
PMV Pharmaceuticals
PMVP
$71.5M
$4.08M 3.31%
3,747,612
+280,928
+8% +$381K
WHWK
11
Whitehawk Therapeutics
WHWK
$192M
$3.36M 2.72%
1,890,245
-209,755
-10% -$548K
LVTX
12
DELISTED
LAVA Therapeutics
LVTX
$2.49M 2.02%
+1,960,610
New +$2.18M
KZR
13
DELISTED
Kezar Life Sciences
KZR
$1.99M 1.61%
408,138
+359,470
+739% +$2.18M
ELEV
14
DELISTED
Elevation Oncology
ELEV
$1.53M 1.24%
+5,890,934
New +$3.36M
ASTC icon
15
Astrotech Corp
ASTC
$15.5M
$1.43M 1.16%
220,410
– –
CNTB
16
Connect Biopharma Holdings
CNTB
$150M
$1.15M 0.93%
2,093,232
– –
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$1.07M 0.87%
+135,095
New +$989K
LONA
18
LeonaBio Inc
LONA
$67.8M
$912K 0.74%
320,067
+42,478
+15% +$188K
MIST icon
19
Milestone Pharmaceuticals
MIST
$148M
$909K 0.74%
1,136,091
– –
LSTA icon
20
Lisata Therapeutics
LSTA
$32.8M
$510K 0.41%
216,853
-67,816
-24% -$184K
TSBX
21
DELISTED
Turnstone Biologics
TSBX
$452K 0.37%
+1,103,386
New +$470K
VTGN icon
22
VistaGen Therapeutics
VTGN
$9.4M
$375K 0.3%
150,000
– –
ALMS
23
Alumis Inc
ALMS
$3.65B
$305K 0.25%
+49,627
New +$289K
NXTC icon
24
NextCure
NXTC
$24.4M
$131K 0.11%
22,795
– –
VRCA icon
25
Verrica Pharmaceuticals
VRCA
$96M
$77.2K 0.06%
17,465
– –
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
TI
Truxt Investmentos Rio De Janeiro, Brazil $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
HCWM
Hidden Cove Wealth Management Bainbridge Island, Washington $156M AUM 16.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

BML Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, BML Capital Management held 31 positions worth $124M, down 23% from $161M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

BML Capital Management deployed $4.08M of net new capital in Q1 2025, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Third Harmonic Bio: 3,824,417 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 83% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Whitehawk Therapeutics, an estimated $548K trimmed.

  • BML Capital Management's largest Q1 2025 buy was Third Harmonic Bio: 3,824,417 shares worth $13.3M.
  • BML Capital Management added most to Kezar Life Sciences in Q1 2025, an estimated $2.18M increase.
  • BML Capital Management's biggest Q1 2025 reduction was Whitehawk Therapeutics, cutting an estimated $548K.
  • BML Capital Management fully exited iShares 0-3 Month Treasury Bond ETF in Q1 2025, selling an estimated $26.1M.
  • BML Capital Management's ten largest holdings make up 86% of its $124M portfolio in Q1 2025.
  • BML Capital Management opened 6 new positions and closed 4 in Q1 2025.
  • BML Capital Management's portfolio value fell 23% quarter-over-quarter to $124M.

Based on BML Capital Management's 13F filing for Q1 2025, filed 7 May 2025.